Kline & Co.

Countries consider challenges and benefits of Rx-to-OTC switches for cholesterol reducers

Published in Cardiovascular Business Week, January 24th, 2006

It is not often that a change from prescription to nonprescription status creates an entirely new category of over-the-counter (OTC) medications, but that is what is set to occur as pharmaceutical companies are attempting to switch their cholesterol-lowering drugs to OTC status in many of the largest markets around the world.

Two recently released studies by Kline & Co. examine this imminent shift and its implications for the healthcare systems of the United States, Germany, and other countries.

"A shift in this class definitely brings significant regulatory and consumer marketing challenges, but there are practical and financial reasons to make the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cardiovascular Business Week

Source: Cardiovascular Business Week (2006-01-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry